A fully human monoclonal antibody that has been found to inhibit interleukin-17A may significantly improve moderate-to-severe plaque psoriasis, according to new phase 2 study data recently released.
Risankizumab Efficacious in Patients With Concomitant Psoriasis and HIV, Study Reports
The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis
Eczema Resources for Your Patients: Week 1
The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques
Editorial Advisory Board Insights for Eczema Awareness Month: Raj Chovatiya, MD, PhD
Spotlighting Advances in Atopic Dermatitis Research and Prevention Strategies